WGS can identify genetic mutations that are diagnostic for certain types of cancer. For example, specific mutations in the BRCA1 and BRCA2 genes are highly indicative of breast and ovarian cancers. By using WGS, clinicians can detect these mutations early, potentially before symptoms appear, allowing for proactive monitoring and early intervention. This can significantly improve patient outcomes.
